GLP-1 Cost Comparison 2026: Ozempic vs Wegovy vs Compounded vs Oral

This GLP-1 cost comparison shows that in June 2026, branded GLP-1 list prices sit near $1,000–$1,350 per month, but manufacturer cash-pay programs cut real out-of-pocket costs to roughly $149–$499. Compounded semaglutide — once the cheap option — is now largely restricted after the FDA declared the shortage resolved. This guide compares every pathway: branded, cash-pay, compounded, and the new oral Wegovy pill.

GLP-1 cost at a glance (June 2026)

• Ozempic (semaglutide injection): ~$1,000/month list; cash-pay via NovoCare often ~$349–$499/month depending on dose
• Wegovy (semaglutide injection): ~$1,349/month list; cash-pay self-pay often ~$149–$399/month under current offers
• Oral Wegovy (semaglutide pill): launched January 2026; starting near ~$149/month cash-pay, ~$25 or less with covered insurance
• Zepbound (tirzepatide injection, the GLP-1/GIP comparator): self-pay single-dose vials $299–$449/month via LillyDirect (as of December 2025)
• Compounded semaglutide: previously $150–$300/month, but the FDA declared the semaglutide shortage resolved (February 2025) and is moving to bar large-scale compounding — broad legal access has largely ended
• Insurance/coverage: the single biggest cost variable; covered copays can fall to $0–$25, while uncovered patients pay cash-pay program rates

Prices below reflect publicly listed manufacturer figures and program terms as of June 2026. Promotional cash-pay pricing is time-limited and changes frequently; always confirm current terms directly with the manufacturer or pharmacy. Prices vary by dose, pharmacy, insurance design, and state. Discuss cost and clinical fit with a licensed healthcare provider before starting any GLP-1 medication.

What is the real list price of Ozempic and Wegovy in 2026?

The "list price" (also called wholesale acquisition cost) is the manufacturer's sticker price before insurance, rebates, or savings programs. It is rarely what a patient actually pays, but it sets the ceiling.

As of June 2026, Ozempic (semaglutide, FDA-approved for type 2 diabetes) carries a list price near $1,000 per month, while Wegovy (semaglutide, FDA-approved for chronic weight management) lists at roughly $1,349 per package per month [VERIFY: exact current WAC figures fluctuate; confirm against NovoCare]. Both are made by Novo Nordisk and contain the same active molecule, semaglutide — the difference is the FDA-approved indication, available doses, and pen design, not the drug itself.

Almost no patient pays the full list price. The number that matters is your net cost after insurance or a cash-pay program, covered below.

For more on how semaglutide works and its approved uses, see our semaglutide complete guide.

What do Ozempic and Wegovy cost with cash-pay programs?

Novo Nordisk runs direct cash-pay channels (NovoCare Pharmacy and self-pay savings offers) that dramatically lower out-of-pocket cost for people paying without insurance.

Under current offers (June 2026):

These figures are introductory and promotional — for example, certain starter doses have been offered at reduced rates only through stated cutoff dates, after which the price rises. Confirm live pricing and eligibility directly with NovoCare before relying on any figure here.

By comparison, Eli Lilly's tirzepatide product Zepbound — a GLP-1/GIP receptor agonist often cross-shopped against Wegovy — offers self-pay single-dose vials through LillyDirect at $299 per month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for higher doses, as announced in December 2025 (Eli Lilly, 2025). See our tirzepatide protocol guide for how tirzepatide differs from semaglutide.

How much does the new oral Wegovy pill cost?

The oral Wegovy pill (oral semaglutide 25 mg for weight management) was approved by the FDA on December 22, 2025 and reached U.S. pharmacies in January 2026 — the first oral GLP-1 cleared specifically for chronic weight management, also indicated to reduce the risk of major adverse cardiovascular events (Novo Nordisk, 2025). Novo Nordisk has stated cash-pay pricing starting near $149 per month, with covered-insurance copays potentially as low as roughly $25 or less.

The oral pill's approval was supported by the Phase 3 OASIS 4 trial. In that 64-week study of 307 adults with overweight or obesity and without diabetes, oral semaglutide 25 mg produced an estimated mean body-weight reduction of 13.6%, versus 2.2% with placebo, under the trial's primary (treatment-policy) estimand (Wharton et al., 2025, N Engl J Med). Per-protocol analyses among adherent completers reported larger reductions, which is why some press figures (around 16.6%) appear higher than the primary-estimand number.

Note the distinction from Rybelsus, an earlier oral semaglutide approved for type 2 diabetes (and, as of October 17, 2025, for reducing the risk of major adverse cardiovascular events in high-risk adults with type 2 diabetes) — Rybelsus is not approved for weight management (Novo Nordisk, 2025). Always confirm which product and indication a price quote refers to. Discuss whether an oral or injectable formulation fits your situation with a licensed healthcare provider.

Why did compounded semaglutide get so much more expensive — or disappear?

For much of 2023–2024, compounded semaglutide was the budget pathway, often $150–$300 per month through telehealth clinics. That window has largely closed.

Federal law (sections 503A and 503B of the Food, Drug, and Cosmetic Act) generally lets pharmacies compound copies of an FDA-approved drug only while that drug is on the FDA shortage list. Once the shortage ends, compounding "essentially a copy" of the approved product is no longer permitted.

The timeline:

• The FDA declared the tirzepatide shortage resolved on December 19, 2024, with enforcement-discretion deadlines for state-licensed (503A) pharmacies on February 18, 2025, and outsourcing (503B) facilities on March 19, 2025 (FDA Declaratory Order, 2024).
• The FDA declared the semaglutide shortage resolved on February 21, 2025, with the 503A compounding deadline on April 22, 2025, and the 503B deadline on May 22, 2025 (FDA, 2025).
• On April 30, 2026, the FDA proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, with a public comment period running through June 29, 2026 — a step toward permanently blocking large-scale compounding of these molecules (FDA, 2026).

The practical result in June 2026: broad, low-cost compounded semaglutide access has largely ended. Narrow exceptions can still exist (for example, a documented clinical need such as a medically necessary dose or formulation not commercially available), but these are case-specific and patient-specific, not a general discount channel.

Is compounded semaglutide a safe way to save money?

Cost is only one part of the picture, and the FDA has flagged real safety concerns with compounded GLP-1 products. Compounded drugs are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality before reaching patients.

In a July 2024 alert, the FDA reported dosing errors with compounded injectable semaglutide, including patients administering 5 to 20 times the intended dose, leading to adverse events such as severe nausea, severe vomiting, and severe hypoglycemia — some requiring hospitalization (FDA, 2024). Errors were linked to unfamiliarity with drawing medication from a vial and confusion between units (milligrams, milliliters, and "units").

If you are weighing a compounded or research-grade source on price alone, our grey-market peptide red flags guide explains COA verification and the red flags to check. Whatever the pathway, consult your healthcare provider before starting or changing any GLP-1 protocol, and never adjust a dose based on cost pressure alone.

Which GLP-1 is the best value: cost vs. results?

"Best value" depends on coverage, dose, and how you weigh price against expected results — and the cheapest option is not always the most effective.

On efficacy, the head-to-head SURMOUNT-5 trial directly compared the two leading molecules. Over 72 weeks in 751 adults with obesity and without diabetes, tirzepatide produced a mean weight reduction of 20.2%, versus 13.7% for semaglutide (Aronne et al., 2025, N Engl J Med). That favors tirzepatide on raw weight loss — but tirzepatide (Zepbound/Mounjaro) is a separate GLP-1/GIP medication, and individual response, side effects, and tolerability vary.

A rough value framework:

• If you have coverage: the covered drug with the lowest copay usually wins — covered copays can fall to $0–$25 regardless of list price.
• If you are paying cash: compare current manufacturer cash-pay programs (Wegovy/Ozempic via NovoCare; Zepbound vials via LillyDirect) rather than list prices, since net cash cost is far lower.
• If you prefer a pill: oral Wegovy is the lowest-friction option, with cash-pay starting near $149/month, though injectable tirzepatide showed greater weight loss in trials.
• Compounded: no longer a reliable budget pathway given the resolved shortage and proposed 503B exclusion.

Cost and clinical suitability should be decided with a licensed healthcare provider, not on price alone. Consult your healthcare provider before starting any GLP-1 protocol.

Frequently asked questions

Q: Is Ozempic or Wegovy cheaper? A: They contain the same drug (semaglutide) but are priced and dosed differently. As of June 2026, Ozempic lists near $1,000/month and Wegovy near $1,349/month, but real cash-pay costs are far lower — often $149–$399/month for Wegovy and roughly $349–$499/month for Ozempic through Novo Nordisk's NovoCare and self-pay programs, depending on dose. With insurance, the covered product with the lowest copay is usually cheapest. Confirm current pricing directly with the manufacturer, as promotional terms change.

Q: How much does compounded semaglutide cost in 2026, and is it still legal? A: Compounded semaglutide once cost roughly $150–$300/month, but the FDA declared the semaglutide shortage resolved in February 2025, with 503A pharmacy compounding deadlines passing in April 2025 and 503B deadlines in May 2025. In April 2026 the FDA proposed excluding semaglutide from the 503B bulks list entirely. Broad low-cost access has largely ended; narrow, patient-specific compounding exceptions can remain. Legal status varies by jurisdiction; consult a lawyer for binding advice.

Q: How much does the oral Wegovy pill cost? A: The oral Wegovy pill (oral semaglutide for weight management), which reached U.S. pharmacies in January 2026, has cash-pay pricing starting near $149/month per Novo Nordisk, with covered-insurance copays potentially around $25 or less. It is the first oral GLP-1 approved specifically for chronic weight management. Pricing and eligibility change frequently — confirm current terms with the manufacturer and discuss suitability with your healthcare provider.

Q: Why is the GLP-1 list price so different from what people actually pay? A: List price (wholesale acquisition cost) is the manufacturer's sticker price before insurance, rebates, and savings programs. Almost no one pays it. Insured patients pay a copay set by their plan (sometimes $0–$25); uninsured patients pay manufacturer cash-pay program rates, which are far below list. Your net cost depends on coverage, dose, pharmacy, and current promotions, so compare net prices — not list prices — across options.

Q: Does insurance cover GLP-1 medications for weight loss? A: Coverage varies widely by plan. Many plans cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro) more readily than for weight management (Wegovy, Zepbound), and some require prior authorization or a documented BMI threshold. Medicare Part D is prohibited by statute from covering medications used solely for weight loss, so it covers GLP-1s only for another approved indication such as type 2 diabetes or cardiovascular risk reduction; for weight-loss-only use, CMS has launched a voluntary Medicare GLP-1 Bridge demonstration offering eligible Part D beneficiaries access at a $50 monthly copay between July 1, 2026 and December 31, 2027 (CMS, 2026). Check your specific formulary and confirm coverage with your insurer and provider.

Q: Is the cheapest GLP-1 the most effective one? A: Not necessarily. In the head-to-head SURMOUNT-5 trial, tirzepatide produced greater mean weight loss than semaglutide (20.2% vs 13.7% at 72 weeks), yet pricing depends on coverage and current cash-pay offers rather than efficacy. The lowest-cost option for you depends on your insurance, dose, and tolerability. Effectiveness and side effects vary by individual, so weigh cost against clinical fit with your healthcare provider.

References

1. Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/
2. Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med. 2025. PMID: 40934115. https://pubmed.ncbi.nlm.nih.gov/40934115/
3. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 2024. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
4. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (semaglutide shortage resolved Feb 21, 2025; 503A deadline Apr 22, 2025; 503B deadline May 22, 2025). https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
5. U.S. Food and Drug Administration. Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products (Dec 19, 2024; 503A deadline Feb 18, 2025; 503B deadline Mar 19, 2025). https://www.fda.gov/media/184606/download
6. U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (proposed Apr 30, 2026; comment period through Jun 29, 2026). https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
7. Eli Lilly and Company. Lilly lowers the price of Zepbound (tirzepatide) single-dose vials (self-pay $299/$399/$449 by dose; Dec 2025). https://investor.lilly.com/news-releases/news-release-details/lilly-lowers-price-zepboundr-tirzepatide-single-dose-vials
8. Novo Nordisk A/S. Wegovy pill approved in the US as first oral GLP-1 for weight management (FDA approval of once-daily oral semaglutide 25 mg, Dec 22, 2025). https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472
9. Novo Nordisk. FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event (Rybelsus, Oct 17, 2025). https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-oral-semaglutide-for-cardiovascular-cv-risk-reduction-in-adults-with-type-2-diabetes-who-are-at-high-risk-including-those-who-have-not-had-a-prior-cv-event-302588005.html
10. Centers for Medicare & Medicaid Services (CMS). Medicare GLP-1 Bridge (statutory weight-loss exclusion; GLP-1s covered only for other approved indications; voluntary $50/month bridge demonstration July 1, 2026–Dec 31, 2027). https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge